Retracted: Successful treatment of pyoderma gangrenosum with anakinra in a patient with Wiskott–Aldrich syndrome
S. Mercuri,G. Paolino,Eduardo De Flammineis,D. Didona,P. Brianti
DOI: https://doi.org/10.1111/dth.12582
2018-03-01
Dermatologic Therapy
Abstract:Dear Editor, Pyoderma gangrenosum (PG) is a rare, chronic, inflammatory disease, characterized by painful papules or pustules that rapidly evolve into ulcers with irregular, undermined, and overhanging violaceous borders (Gameiro, Pereira, Cardoso, & Gonçalo, 2015). PG is more frequent on lower extremities and in women between 20 and 50 years of age (Gameiro et al., 2015). Up to 70% of PG patients show an underlying systemic disease, including inflammatory bowel diseases, arthritis, and hematological malignancies (Gameiro et al., 2015). Wiskott–Aldrich syndrome (WAS) is a rare X-linked primary immunodeficiency characterized by severe immunodeficiency, thrombocytopenia, and eczema (Buchbinder, Nugent, & Fillipovich, 2014). The WAS gene (Xp11.22–p11.23) encodes the WAS protein, involved in actin polymerization and associated coupling of receptor engagement, signaling events, and cytoskeletal rearrangement (Buchbinder et al., 2014). A 14-year-old Caucasian male presented to our Institute with a 5month history of PG lesions (Figure 1a,b). His personal medical history was positive for WAS. Whole genome sequencing detected the mutation inv(X)g.5721–11840, a rare inversion in WAS gene. In addition, the patient medical history was also positive for arthritis, Henoch– Sch€ onlein purpura, and a Crohn-like colitis, that led to subtotal colectomy and ileostomy. Several therapies were started to manage PG, including systemic metil-prednisolone (5 mg/kg/day), minocycline (100 mg twice daily), cyclosporine (5 mg kg/day), and adalimumab (80 mg at week 0, 40 mg at week 1, followed by 40 mg every 15 days). However, no PG improvement was observed. Therefore, we decided to start anakinra 100 mg once a day. Two months after a complete